H&T Presspart has entered a collaborative partnership with Hovione Technology to expand its drug delivery systems portfolio for respiratory care.
The company has purchased the global rights to manufacture and commercialise Hovione’s capsule-based dry powder inhaler (DPI) and has upgraded the product, naming it PowdAir Plus.
H&T Presspart chairman Peter Schmelzer said: “This is a strategically significant partnership and underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialisation of novel drug delivery solutions for respiratory patients.
“This partnership supports our strategy to respond to the rapidly growing demand for DPIs across a range of needs, while it focuses on providing a solution for developing markets.”
The neat, compact and affordable PowdAir Plus features an all-plastic four-component design that enables ease of use and reduces manufacturing assembly and production costs.
Hovione Technology CEO Peter Villax said: “With our expertise in DPI invention, design and development, and Presspart’s mastery of large-scale industrialisation and global distribution, we are very confident about success.”
PowdAir Plus is available as a complete unit without any separate parts.
The device can be used with any dry powder medicines as it is compatible with all size three capsule types.
The pharmaceutical firms working with H&T on PowdAir Plus will have access to its manufacturing capabilities and experience in industrialising products, while they will also acquire Hovione’s expertise in formulation and manufacturing of active pharmaceutical ingredients (APIs).
Image: PowdAir Plus. Photo: courtesy of H&T Presspart.